ORIGINAL PAPER
The prevalence and correlation of depression and anxiety with disease activity in rheumatoid arthritis
More details
Hide details
1 |
Health Research Center, Master of Biostatist and Epidemiology, Babol University of Medical Science, Babol, Iran. |
2 |
Clinical research development unit of Rouhani, Babol University of Medical Sciences, Babol, Iran |
3 |
Student research ccommittee, Babol University of Medical Sciences, Babol, Iran. |
4 |
Clinical research development unit of Rouhani Hospital,Babol University of Medical Sciences, Babol. |
CORRESPONDING AUTHOR
Mansour Babaei
Clinical research development unit of Rouhani Hospital,Babol University of Medical Sciences, Babol.
Submission date: 2022-06-12
Final revision date: 2022-08-12
Acceptance date: 2022-09-25
Online publication date: 2023-02-01
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Depression and anxiety share similar symptoms with rheumatoid arthritis (RA) and these conditions are often not diagnosed or overlooked in RA. This study aimed to determine the prevalence of depression/anxiety in RA and their correlation with RA activity.
Material and methods:
Rheumatoid arthritis patients who presented at a rheumatology clinic were selected consecutively. The diagnosis of RA was confirmed by the ACR/EULAR criteria, disease activity was assessed by Disease Activity Score based on the 28-joint count (DAS28) and patients with DAS28 > 2.6 were considered to have active RA. The diagnosis of depression and anxiety was made by the Hospital Anxiety and Depression Scale (HADS). The Pearson test was used to determine the correlation between DAS28 and HADS scores.
Results:
Two-hundred patients (female, 82%) with a mean age of 53.5 ±10.1 years and mean disease duration of 6.6 ±6.8 years were studied. Depression was diagnosed in 27 (13.5%) patients and anxiety in 38 (19%) patients. The DAS28 score correlated positively with depression (r = 0.173, p = 0.014) and anxiety score (r = 0.229, p = 0.001). In multiple logistic regression analysis after adjustment for all covariates, age < 40 years and female sex were independently associated with RA activity in patients with depression, with OR = 4.21 (p = 0.002) and OR = 3.56 (p = 0.028) respectively.
Conclusions:
These findings indicate that depression and anxiety are prevalent in RA and correlate positively with active disease in particular in depressive female patients aged < 40 years.
REFERENCES (30)
1.
Bruce TO. Comorbid depression in rheumatoid arthritis: pathophysiology and clinical implications. Curr Psychiatry Rep 2008; 10: 258–264, DOI: 10.1007/s11920-008-0042-1.
2.
Jacob L, Rockel T, Kostev K. Depression risk in patients with rheumatoid arthritis in the United Kingdom. Rheumatol Ther 2017; 4: 195–200, DOI: 10.1007/s40744-017-0058-2.
3.
Machin A, Hider S, Dale N, Chew-Graham C. Improving recognition of anxiety and depression in rheumatoid arthritis: a qualitative study in a community clinic. Br J Gen Pract 2017; 67: e531–e537, DOI: 10.3399/bjgp17X691877.
4.
Matcham F, Rayner L, Steer S, Hotopf M. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford) 2013; 52: 2136–2148, DOI: 10.1093/rheumatology/ket169.
5.
Qiu X-J, Zhang X-L, Cai L-S, et al. Rheumatoid arthritis and risk of anxiety: a meta-analysis of cohort studies. Clin Rheumatol 2019; 38: 2053–2061, DOI: 10.1007/s10067-019-04502-8.
6.
Peterson S, Piercy J, Blackburn S, et al. The multifaceted impact of anxiety and depression on patients with rheumatoid arthritis. BMC Rheumatol 2019; 3: 43, DOI: 10.1186/s41927-019-0092-5.
7.
Vallerand IA, Patten SB, Barnabe C. Depression and the risk of rheumatoid arthritis. Curr Opin Rheumatol 2019; 31: 279–284, DOI: 10.1097/BOR.0000000000000597.
8.
Więdłocha M, Marcinowicz P, Krupa R, et al. Effect of antidepressant treatment on peripheral inflammation markers – A meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2018; 80(Pt C): 217–226, DOI: 10.1016/j.pnpbp.2017.04.026.
9.
Lu M-C, Guo H-R, Lin M-C, et al. Bidirectional associations between rheumatoid arthritis and depression: a nationwide longitudinal study. Sci Rep 2016; 6: 20647, DOI: 10.1038/srep20647.
10.
DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000; 160: 2101–2107, DOI: 10.1001/archinte.160.14.2101.
11.
Kojima M, Kojima T, Suzuki S, et al. Depression, inflammation, and pain in patients with rheumatoid arthritis. Arthritis Rheum 2009; 61: 1018–1024, DOI: 10.1002/art.24647.
12.
Ang DC, Choi H, Kroenke K, Wolfe F. Comorbid depression is an independent risk factor for mortality in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1013–1019.
13.
Kay J, Upchurch KS. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford) 2012; 51(suppl_6): vi5-vi9, DOI: 10.1093/rheumatology/kes279.
14.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361–370, DOI: 10.1111/j.1600-0447.1983.tb09716.x.
15.
Kaviani H, Seyfourian H, Sharifi V, Ebrahimkhani N. Reliability and validity of anxiety and depression hospital scales (HADS): Iranian patients with anxiety and depression disorders. Tehran University Medical Journal 2009; 67: 379–385.
16.
Ruhaila AR, Chong CH. Self-reported symptoms of depression, anxiety and stress among patients with Rheumatoid Arthritis in a Malaysian rheumatology centre – prevalence and correlates. Med J Malaysia 2018; 73: 226–232.
17.
Mostafa H, Radwan A. The relationship between disease activity and depression in Egyptian patients with rheumatoid arthritis. The Egyptian Rheumatologist 2013; 35: 193–199.
18.
Anderson J, Caplan L, Yazdany J, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) 2012; 64: 640–647, DOI: 10.1002/acr.21649.
19.
Sadeghirad B, Haghdoost A-A, Amin-Esmaeili M, et al. Epidemiology of major depressive disorder in Iran: a systematic review and meta-analysis. Int J Prev Med 2010; 1: 81–91.
20.
Matcham F, Ali S, Irving K, et al. Are depression and anxiety associated with disease activity in rheumatoid arthritis? A prospective study. BMC Musculoskel Disord 2016; 17: 155, DOI: 10.1186/s12891-016-1011-1.
21.
Boer AC, Huizinga TW, van der Helm-van Mil AH. Depression and anxiety associate with less remission after 1 year in rheumatoid arthritis. Ann Rheum Dis 2019; 78: e1, DOI: 10.1136/annrheumdis-2017-212867.
22.
Michelsen B, Kristianslund EK, Sexton J, et al. Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study. Ann Rheum Dis 2017; 76: 1906–1910, DOI: 10.1136/annrheumdis-2017-211284.
23.
Astin JA, Beckner W, Soeken K, et al. Psychological interventions for rheumatoid arthritis: A meta-analysis of randomized controlled trials. Arthritis Care Res 2002; 47: 291–302, DOI: 10.1002/art.10416.
24.
Abbott R, Whear R, Nikolaou V, et al. Tumour necrosis factor-α inhibitor therapy in chronic physical illness: A systematic review and meta-analysis of the effect on depression and anxiety. J Psychosom Res 2015; 79: 175–184, DOI: 10.1016/j.jpsychores.2015.04.008.
25.
Figueiredo-Braga M, Cornaby C, Cortez A, et al. Influence of biological therapeutics, cytokines, and disease activity on depression in rheumatoid arthritis. J Immunol Res 2018; 2018: 5954897, DOI: 10.1155/2018/5954897..
26.
Kuriya B, Joshi R, Movahedi M, et al. High disease activity is associated with self-reported depression and predicts persistent depression in early rheumatoid arthritis: results from the ontario best practices research initiative. J Rheumatol 2018; 45: 1101–1108, DOI: 10.3899/jrheum.171195.
27.
Baeza-Velasco C, Olié E, Béziat S, et al. Determinants of suboptimal medication adherence in patients with a major depressive episode. Depress Anxiety 2019; 36: 244–251, DOI: 10.1002/da.22852.
28.
Edwards RR, Cahalan C, Mensing G, et al. Pain, catastrophizing, and depression in the rheumatic diseases. Nat Rev Rheumatol 2011; 7: 216–224, DOI: 10.1038/nrrheum.2011.2.
29.
Krishnadas R, Krishnadas R, Cavanagh J. Sustained remission of rheumatoid arthritis with a specific serotonin reuptake inhibitor antidepressant: a case report and review of the literature. J Med Case Rep 2011; 5: 112, DOI: 10.1186/1752-1947-5-112.
30.
Kappelmann N, Lewis G, Dantzer R, et al. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Mol Psychiatry 2018; 23: 335–343, DOI: 10.1038/mp.2016.167.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (
https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.